Current page location

Biotherapeutics Translational Research Center

Biotherapeutics Translational Research Center
Objectives
Development of bio new drug platform technology for target therapy of rare diseases
  • Identification of target based on multi-function antibody library and development of control technology
  • Development of gene control technology for the development of gene therapy
Researcher
    Click on the name
researchers and research statement
name research fields
Jeong Ki Min
/ Associate Director
  • Agiogenesis/ inflammation control, cancer target/regulation technology, control of stem cell differentiation
Jang-Seong Kim
/ Principal Researcher
(Concurrent Position)
  • Development of anticancer agents, research on matastasis, development of new drug
Dong Uk Kim
/ Principal Researcher
  • Research on degenerative brain disease using yeast model
  • High-speed medicine application point search system in yeast
  • Interaction between medicine-protein using network algorithm
Young Il Yeom
/ Principal Researcher
  • Identification of cancer specific metabolism target treatment material
Lee Jeong Woong
/ Principal Researcher
  • Production of knock-out cloned pig
  • Functional genomics from animal models of diseases
Dong Chul Lee
/ Senior Researcher
  • Research on protein function related to lactic acid/metabolic signal
Yeon-Gu Kim
/ Senior Researcher
  • Biochemical engineering
  • Animal cell culture
Jong Gil Park
/ Researcher
  • Cardiovascular and metabolic diseases
Lee Sang Hyun
/ Researcher
  • Neuropharmacology
Jang Wook Lee
/ Researcher
  • Nanomedicine, Macromolecule delivery system, Cancer diagnosis/therapy
Tae Su Han
/ Researcher
  • Cancer, Micro RNA
research areas
  • Identification of target that adjusts cancer/agiogenesis and blood vessel inflammation and development of control technology
    • Identification of target based on multi-function antibody library system and development of antibody
    • Regulating endothelium differentiation based on stem cell
  • Finding out the resistance to drug and metastasis regulation and development of control technology
    • Development of a new drug through translational research between basic-clinical research
  • Development of treatment targeting cancer specific cell metabolism-signal and development of application technology
    • Role of cancer cell metabolome lactic acid and research on mechanism
    • Research on therapeutic technology through controlling of lactic acid signaling system
  • Identification of gene related to the production of immunodeficient pig
    • Research on the mechanism of factors that cause immune rejection response
  • Production of animal of diseases and functional research
    • Production of gene deficient and mutated animals using gene editing system
    • Research on the molecular biological and physiological functions using animal model
Achievements
  • Providing cancer/blood vessel treatment technology through finding out the function of new protein that regulates agiogenesis and functions
    • Technology that activates/controls agiogenesis based on antibody
    • Cell treatment technology by establishing endothelium differentiation regulation platform
  • Identification of phosphatase enzyme that regulates blood vessel inflammation/permeability and finding out mechanism for new inflammation regulation
  • Finding out the new function of lactic acid of cell metabolome related to causing diseases
    • Finding out the new signaling mechanism of hypoxia causing disease and physiological and pathological roles
    • Finding out the major factors that regulate the function of lactic acid, which is cancer specific metabolic product
  • Finding out the factors that regulate resistance to drug and metastasis, development of control technology and establishment of basic-clinical translational research
  • Production of pig T-cell, B-cell immune deficient cell line
  • Establishment of the genetically modified cell line for the production of mini cloned pig for heterograft transplant
Outstanding Papers
  • Jeong-Ki Min (corresponding) J. Hepatology. 63:1429-1439.
    • Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression.
  • Jang Seong Kim (first) Jeong-Ki Min (corresponding) Biomaterials 51:119-28
    • Stimulation of angiogenesis and survival of endothelial cells by human monoclonal Tie2 receptor antibody
  • Jeong-Ki Min (corresponding) Clin. Cancer Res. 18(12):3270-80
    • Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor
  • Jeong-Ki Min (first) J. Clin. Invest. 121(5):1882-93
    • The WNT antagonist Dickkopf2is a novel promoter of angiogenesis. In rodents and human endothelial cells.
  • Dong Chul Lee (first) and Young Il Yeom (corresponding) Cell 161(3):595-609.
    • A lactate-induced response to hypoxia.
  • Young Il Yeom (corresponding) Exp Cell Res. 336(1):119-29.
    • Pyruvate kinase enzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.
  • Jang Seong Kim (Co-corresponding) Clin Cancer Res. 19(19):5340-50.
    • Characterization of CD45-/CD31+/CD105+ circulating cells in the peripheral blood of patients with gynecologic malignancies
  • Jeong-Woong Lee (Second) J. Neuroscience, 35(11):4587-5498
    • Mutations in the microtubule-associated protein 1A (Map1a) gene cause Purkinje cell degeneration
  • Jeong-Woong Lee (Corresponding) Life Science, 132:49-54
    • Small heterodimer partner-interacting leucine zipper protein inhibits adipogenesis by regulating peroxisome proliferator-activated receptor γ activity
  • Jeong-Woong Lee (Corresponding) Bone, 61:10-8
    • SMILE inhibits BMP-2-induced expression of osteocalcin by suppressing the activity of the RUNX2 transcription factor in MC3T3E1 cells